=== Totals ===
FDA pediatric indications (1997–2023): 59
Also FDA adult approvals (same indication): 50 (84.7%)
Unique drug entities: 44
Unique drugs with HC pediatric approval: 18/44

=== Health Canada (HC) pediatric approvals ===
HC pediatric approvals: 21 (35.6%)
… pediatric-only approvals: 4
… pediatric+adult approvals: 17
NOC among HC pediatric approvals: 11 (52%)
NOC/c among HC pediatric approvals: 10 (48%)

=== No HC pediatric approval: reasons ===
Count: 38
hc_pediatric_reason
not indicated                                23
not indicated for specific fda indication     7
not found                                     4
under review                                  2
cancelled                                     2
… of which no submission/cancelled: 6 (10.2%)

=== Timelines: FDA → HC ===
Adult indications:   median=316.0 days (IQR 218.5-634.5), n=35
Pediatric indications:median=244.0 days (IQR 208.0-639.0), n=21

HC before FDA (adult):
- Asparaginase erwinia chrysanthemi
- Rituximab
HC before FDA (pediatric):
- Asparaginase erwinia chrysanthemi
- Pegaspargase

=== HC submission → HC approval (pediatric) ===
median=295.0 days (IQR 262.0-434.0), n=13

=== CADTH (pediatric) ===
pediatric_cadth_status
not reviewed           43
restricted positive    11
under review            3
positive                1
negative                1
Submitted to CADTH without HC pediatric approval: 4
Positive/restricted CADTH without HC pediatric approval:
- Arsenic trioxide: positive
- Cabozantinib: restricted positive

HC-approved pediatric → CADTH review timing:
pre_post
post-NOC    6
pre-NOC     5
unknown     1

HC-approved pediatric → CADTH recommendation types:
pediatric_cadth_status
restricted positive    10
not reviewed            9
negative                1
under review            1

=== pCPA (pediatric, among HC-approved) ===
pediatric_pcpa_status
not reviewed            11
LOI                      8
not pursued              1
negotiations ongoing     1
No. of LOIs for indications without HC pediatric approval: 0

=== Cancer Care Ontario (CCO) listing ===
Total CCO pediatric indications: 18
… of which HC pediatric-approved: 12
CCO programs (counts):
pediatric_cco_program
New Drug Funding Program        9
Exceptional Access Program      4
Ontario General Benefit         3
High Cost Therapy Program       1
(CAR) T-cell Therapy Program    1

=== Median timelines (days) ===
CADTH submission → recommendation: median=194.0 days (IQR 180.0-283.0), n=13
pCPA consideration → negotiation completed: median=124.0 days (IQR 24.0-171.5), n=8
HC submission ↔ CADTH submission difference: median=369.5 days (IQR 267.0-787.2), n=10
Pre-NOC overlap (CADTH submission before HC approval): median=58.0 days (IQR 15.0-63.0), n=5
HC approval → CADTH recommendation: median=252.0 days (IQR 127.0-391.5), n=11
HC approval → pCPA completion:     median=519.0 days (IQR 286.0-654.0), n=9
CADTH recommendation → pCPA completion: median=157.0 days (IQR 76.0-204.0), n=9
HC submission → pCPA completion: median=764.0 days (IQR 606.0-1023.8), n=8

=== Yearly counts (Figure 2 support) ===
FDA pediatric approvals per year:
pediatric_fda_approval
2000     1
2002     1
2003     2
2004     1
2005     1
2006     2
2010     1
2011     1
2012     1
2013     2
2014     1
2015     1
2016     1
2017     8
2018    11
2019     1
2020     7
2021     7
2022     6
2023     3
HC pediatric approvals per year:
pediatric_hc_approval
1997.0    1
1998.0    1
2007.0    2
2009.0    1
2011.0    1
2013.0    1
2014.0    1
2017.0    1
2018.0    4
2019.0    2
2021.0    2
2022.0    3
2023.0    1

=== Canada-side timelines for Table 1 drugs ===

Blinatumomab:
- Blinatumomab: HC→CADTH_sub=-63, CADTH_sub→Rec=180, HC→Rec=117
- Blinatumomab: HC→CADTH_sub=32, CADTH_sub→Rec=283, HC→Rec=315

Dinutuximab:
- Dinutuximab: HC→CADTH_sub=-58, CADTH_sub→Rec=176, HC→Rec=118

Tisagenlecleucel:
- Tisagenlecleucel: HC→CADTH_sub=nan, CADTH_sub→Rec=nan, HC→Rec=132
